300357 我武生物
已收盘 10-30 15:00:00
资讯
新帖
简况
我武生物（300357）10月29日主力资金净买入281.31万元
证券之星 · 09:12
我武生物（300357）10月29日主力资金净买入281.31万元
开源证券：给予我武生物买入评级
证券之星 · 10-28 12:51
开源证券：给予我武生物买入评级
我武生物（300357）10月26日主力资金净买入1567.42万元
证券之星 · 10-27
我武生物（300357）10月26日主力资金净买入1567.42万元
【机构调研记录】瑞达基金调研好太太、我武生物
证券之星 · 10-27
【机构调研记录】瑞达基金调研好太太、我武生物
【机构调研记录】浙商基金调研我武生物
证券之星 · 10-27
【机构调研记录】浙商基金调研我武生物
我武生物涨8.30%，开源证券一个月前给出“买入”评级
证券之星 · 10-26
我武生物涨8.30%，开源证券一个月前给出“买入”评级
生物制品板块异动上涨，我武生物上涨超5%
证券之星 · 10-26
生物制品板块异动上涨，我武生物上涨超5%
我武生物（300357）2026年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 10-25
我武生物（300357）2026年三季报简析：营收净利润同比双双增长，盈利能力上升
我武生物(300357)9月30日股东户数3.92万户，较上期增加11.09%
证券之星 · 10-24
我武生物(300357)9月30日股东户数3.92万户，较上期增加11.09%
我武生物最新公告：前三季度净利润同比增长13.46%
证券之星 · 10-23
我武生物最新公告：前三季度净利润同比增长13.46%
股市必读：我武生物新发布《关于获得S01D片药物临床试验批准通知书的公告》
证券之星 · 10-21
股市必读：我武生物新发布《关于获得S01D片药物临床试验批准通知书的公告》
我武生物(300357.SZ)：S01D片药物临床试验申请获得批准
智通财经 · 10-20
我武生物(300357.SZ)：S01D片药物临床试验申请获得批准
股市必读：我武生物新发布《关于完成工商变更登记并换发营业执照的公告》
证券之星 · 10-19
股市必读：我武生物新发布《关于完成工商变更登记并换发营业执照的公告》
我武生物：2026年3月该公司不再纳入上市公司合并报表范围
证券之星 · 10-16
我武生物：2026年3月该公司不再纳入上市公司合并报表范围
股市必读：我武生物（300357）10月15日董秘有最新回复
证券之星 · 10-16
股市必读：我武生物（300357）10月15日董秘有最新回复
我武生物（300357）10月13日主力资金净卖出170.19万元
证券之星 · 10-14
我武生物（300357）10月13日主力资金净卖出170.19万元
股市必读：我武生物新发布《关于获得人脐带间充质干细胞II型注射液药物临床试验批准通知书的公告》
证券之星 · 10-13
股市必读：我武生物新发布《关于获得人脐带间充质干细胞II型注射液药物临床试验批准通知书的公告》
我武生物最新公告：子公司获人脐带间充质干细胞II型注射液临床试验批准
证券之星 · 10-11
我武生物最新公告：子公司获人脐带间充质干细胞II型注射液临床试验批准
我武生物（300357）9月30日主力资金净卖出1080.97万元
证券之星 · 10-08
我武生物（300357）9月30日主力资金净卖出1080.97万元
股市必读：我武生物新发布《第六届董事会第五次会议决议公告》
证券之星 · 10-08
股市必读：我武生物新发布《第六届董事会第五次会议决议公告》
加载更多
公司概况
公司名称：
浙江我武生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2014-01-21
主营业务：
浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。
发行价格：
20.05
{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":21.46,"timestamp":1793343825000,"preClose":21.2,"halted":0,"volume":13890106,"delay":0,"changeRate":0.0123,"floatShares":474000000,"shares":524000000,"eps":0.8163,"marketStatus":"已收盘","change":0.26,"latestTime":"10-30 15:00:00","open":21.19,"high":21.98,"low":20.98,"amount":299000000,"amplitude":0.0472,"askPrice":21.47,"askSize":84,"bidPrice":21.46,"bidSize":73,"shortable":0,"etf":0,"ttmEps":0.8163,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":21.2,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":23.32,"lowLimit":19.08,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":3.79,"roa":"--","peRate":26.289354,"roe":"14.07%","epsLYR":0.7276,"committee":0.028668,"marketValue":11236000000,"turnoverRate":0.0293,"status":0,"floatMarketCap":10183000000},"requestUrl":"/m/hq/s/300357","defaultTab":"news","newsList":[{"id":"2679736259","title":"我武生物（300357）10月29日主力资金净买入281.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679736259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679736259?lang=zh_cn&edition=full","pubTime":"2026-10-30 09:12","pubTimestamp":1793322764,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月29日收盘，我武生物报收于21.2元，上涨0.43%，换手率1.79%，成交量8.68万手，成交额1.83亿元。10月29日的资金流向数据方面，主力资金净流入281.31万元，占总成交额1.53%，游资资金净流入236.88万元，占总成交额1.29%，散户资金净流出518.18万元，占总成交额2.83%。融券方面，融券卖出2.95万股，融券偿还3.76万股，融券余量12.73万股，融券余额269.88万元。我武生物主营业务：过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000016761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678743439","title":"开源证券：给予我武生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2678743439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678743439?lang=zh_cn&edition=full","pubTime":"2026-10-28 12:51","pubTimestamp":1793163067,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,阮帅近期对我武生物进行研究并发布了研究报告《公司信息更新报告：业绩稳健增长，黄花蒿花粉滴剂快速放量》，给予我武生物买入评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。)本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800025783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678630143","title":"我武生物（300357）10月26日主力资金净买入1567.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678630143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678630143?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:02","pubTimestamp":1793062978,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月26日收盘，我武生物报收于21.0元，上涨8.3%，换手率4.34%，成交量21.09万手，成交额4.36亿元。10月26日的资金流向数据方面，主力资金净流入1567.42万元，占总成交额3.59%，游资资金净流出2299.43万元，占总成交额5.27%，散户资金净流入732.01万元，占总成交额1.68%。融券方面，融券卖出9.89万股，融券偿还1.08万股，融券余量17.74万股，融券余额372.54万元。我武生物主营业务：过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700011234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678811043","title":"【机构调研记录】瑞达基金调研好太太、我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2678811043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678811043?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:03","pubTimestamp":1793059407,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月26日披露的机构调研信息，瑞达基金近期对2家上市公司进行了调研，相关名单如下：1）好太太 调研纪要：毛利率受核心零部件自供、自动化产线等正向因素支撑，公司从采购、制造、产品、渠道等多维度进行成本管控。2）我武生物 调研纪要：公司通过组织架构改革、合规推广和激励优化实现收入利润双增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700010026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0256","603848","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678110177","title":"【机构调研记录】浙商基金调研我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2678110177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678110177?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:03","pubTimestamp":1793059402,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月26日披露的机构调研信息，浙商基金近期对1家上市公司进行了调研，相关名单如下：1）我武生物 调研纪要：公司通过组织架构改革、合规推广和激励优化实现收入利润双增长。浙商基金成立于2010年，截至目前，资产管理规模254.17亿元；资产管理规模197.29亿元；管理公募基金数74只；旗下公募基金经理12人。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700010023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678163967","title":"我武生物涨8.30%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2678163967","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678163967?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:42","pubTimestamp":1793004155,"startTime":"0","endTime":"0","summary":"今日我武生物涨8.30%，收盘报21.0元。2026年8月28日，开源证券研究员余汝意,阮帅发布了对我武生物的研报《公司信息更新报告：2026上半年稳健增长，黄花蒿花粉滴剂快速放量》，该研报对我武生物给出“买入”评级。研报中预计公司2026-2028年归母净利润分别为4.51/5.43/6.47亿元，当前股价对应PE分别为26.6/22.1/18.5倍，考虑公司黄花蒿花粉滴剂快速放量，维持“买入”评级。我武生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600022072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678158385","title":"生物制品板块异动上涨，我武生物上涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678158385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678158385?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:03","pubTimestamp":1792980222,"startTime":"0","endTime":"0","summary":"10月26日，生物制品板块异动上涨，截至发稿，我武生物上涨5.52%，报20.46元，换手率1.44%，成交额1.42亿元。消息面上，10月23日，公司披露2026年三季报，前三季度实现营业收入9.10亿元，同比增长6.64%；归母净利润3.91亿元，同比增长13.46%。其中第三季度单季营业收入3.96亿元，同比增长7.24%；归母净利润1.78亿元，同比增长5.94%，较第二季度单季0.94亿元环比增长88.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026102600006052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678185258","title":"我武生物（300357）2026年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2678185258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678185258?lang=zh_cn&edition=full","pubTime":"2026-10-25 06:11","pubTimestamp":1792879881,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期我武生物发布2026年三季报。截至本报告期末，公司营业总收入9.1亿元，同比上升6.64%，归母净利润3.91亿元，同比上升13.46%。按单季度数据看，第三季度营业总收入3.96亿元，同比上升7.24%，第三季度归母净利润1.78亿元，同比上升5.94%。本报告期我武生物盈利能力上升，毛利率同比增幅0%，净利率同比增幅7.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500000718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677190474","title":"我武生物(300357)9月30日股东户数3.92万户，较上期增加11.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677190474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677190474?lang=zh_cn&edition=full","pubTime":"2026-10-24 17:11","pubTimestamp":1792833084,"startTime":"0","endTime":"0","summary":"证券之星消息，近日我武生物披露，截至2026年9月30日公司股东户数为3.92万户，较6月30日增加3912.0户，增幅为11.09%。在生物制品行业个股中，我武生物股东户数高于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.62万户。从股价来看，2026年6月30日至2026年9月30日，我武生物区间跌幅为12.25%，在此期间股东户数增加3912.0户，增幅为11.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400014210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677092239","title":"我武生物最新公告：前三季度净利润同比增长13.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677092239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677092239?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:30","pubTimestamp":1792758606,"startTime":"0","endTime":"0","summary":"我武生物公告称，第三季度营业收入为3.96亿元，同比增长7.24%；净利润为1.78亿元，同比增长5.94%。前三季度营业收入为9.10亿元，同比增长6.64%；净利润为3.91亿元，同比增长13.46%。注：公司Q3净利润1.78亿，Q2净利润0.94亿，据此计算，Q3净利润环比增长88%。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300041475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677696613","title":"股市必读：我武生物新发布《关于获得S01D片药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677696613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677696613?lang=zh_cn&edition=full","pubTime":"2026-10-21 02:15","pubTimestamp":1792520111,"startTime":"0","endTime":"0","summary":"截至2026年10月20日收盘，我武生物报收于19.26元，上涨1.05%，换手率0.75%，成交量3.64万手，成交额6945.7万元。当日关注点交易信息汇总：10月20日主力资金净流出388.57万元，占总成交额5.59%。公司公告汇总：我武生物收到国家药监局签发的S01D片临床试验批准通知书，该化学药品1类新药拟用于治疗成人耐药肺结核，目前国内外尚无相同化学药物获批上市。公司后续将推进I期至III期临床试验，研发及上市进程存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676650796","title":"我武生物(300357.SZ)：S01D片药物临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2676650796","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676650796?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:53","pubTimestamp":1792486396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物(300357.SZ)发布公告，日前，公司从国家药品监督管理局政务服务门户网站下载获得《药物临床试验批准通知书》，由公司提交的S01D片药物临床试验申请获得批准。该药品拟用于治疗成人耐药肺结核。本品药物临床试验申请获得批准，是公司在抗耐药肺结核药物领域重要的研发节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","300357","BK0028","IBBQ","BK0239","BMED","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676573159","title":"股市必读：我武生物新发布《关于完成工商变更登记并换发营业执照的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676573159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676573159?lang=zh_cn&edition=full","pubTime":"2026-10-19 03:33","pubTimestamp":1792351989,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘，我武生物报收于18.87元，下跌0.42%，换手率1.23%，成交量5.95万手，成交额1.14亿元。当日关注点交易信息汇总：10月16日主力资金净流出176.04万元，占总成交额1.54%。公司公告汇总关于完成工商变更登记并换发营业执照的公告浙江我武生物科技股份有限公司已完成工商变更登记，取得浙江省市场监督管理局换发的《营业执照》；法定代表人变更为陈燕霓；胡沐霜任公司总经理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900001080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675562139","title":"我武生物：2026年3月该公司不再纳入上市公司合并报表范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2675562139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675562139?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:24","pubTimestamp":1792139068,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物10月16日在投资者关系平台上答复投资者关心的问题。我武生物回复：投资者您好，2026年3月，您提及的公司增资扩股引入新股东，交易完成后，上市公司持有的该公司股权比例被动稀释，丧失控制权，该公司不再纳入上市公司合并报表范围，上市公司对该公司的长期股权投资按权益法核算，按持股比例确认其归属于上市公司股东的净利润。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600027552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675534190","title":"股市必读：我武生物（300357）10月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2675534190","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675534190?lang=zh_cn&edition=full","pubTime":"2026-10-16 02:13","pubTimestamp":1792087989,"startTime":"0","endTime":"0","summary":"截至2026年10月15日收盘，我武生物报收于18.95元，下跌0.63%，换手率1.13%，成交量5.48万手，成交额1.05亿元。董秘最新回复投资者： 什么时候出业绩预告？董秘： 投资者您好，公司2026年第三季度具体经营情况请关注公司后续披露的2026年第三季度报告。当日关注点交易信息汇总：10月15日主力资金净流出610.15万元，占总成交额5.84%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600002328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675628399","title":"我武生物（300357）10月13日主力资金净卖出170.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675628399","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675628399?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:17","pubTimestamp":1791940630,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，我武生物报收于19.51元，下跌1.96%，换手率1.31%，成交量6.38万手，成交额1.24亿元。10月13日的资金流向数据方面，主力资金净流出170.19万元，占总成交额1.37%，游资资金净流出265.28万元，占总成交额2.13%，散户资金净流入435.46万元，占总成交额3.5%。融券方面，融券卖出2900.0股，融券偿还3600.0股，融券余量6.19万股，融券余额120.77万元。我武生物主营业务：过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400008455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675804479","title":"股市必读：我武生物新发布《关于获得人脐带间充质干细胞II型注射液药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675804479","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675804479?lang=zh_cn&edition=full","pubTime":"2026-10-13 02:03","pubTimestamp":1791828195,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘，我武生物报收于19.9元，下跌0.45%，换手率1.3%，成交量6.29万手，成交额1.26亿元。当日关注点交易信息汇总：10月12日主力资金净流入381.09万元，占总成交额3.02%。公司公告汇总：子公司“人脐带间充质干细胞II型注射液”获国家药监局临床试验批准，适应症为脓毒症和（或）脓毒性休克，注册分类为治疗用生物制品1类。该产品注册分类为治疗用生物制品1类，目前国内外尚无同类干细胞药物获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674142768","title":"我武生物最新公告：子公司获人脐带间充质干细胞II型注射液临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674142768","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674142768?lang=zh_cn&edition=full","pubTime":"2026-10-11 16:29","pubTimestamp":1791707372,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司间接控股子公司浙江我武干细胞科技有限公司获国家药监局批准，开展人脐带间充质干细胞II型注射液治疗脓毒症和(或)脓毒性休克的I期、II期、III期临床试验。该药品注册分类为治疗用生物制品1类。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101100003742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049010","title":"我武生物（300357）9月30日主力资金净卖出1080.97万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673049010?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:08","pubTimestamp":1791421716,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，我武生物报收于20.33元，上涨2.57%，换手率2.12%，成交量10.28万手，成交额2.1亿元。9月30日的资金流向数据方面，主力资金净流出1080.97万元，占总成交额5.16%，游资资金净流出898.32万元，占总成交额4.29%，散户资金净流入1979.29万元，占总成交额9.44%。融券方面，融券卖出700.0股，融券偿还6800.0股，融券余量7.12万股，融券余额144.75万元。我武生物主营业务：过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800003027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673144250","title":"股市必读：我武生物新发布《第六届董事会第五次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673144250","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673144250?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:28","pubTimestamp":1791394090,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第五次会议决议公告浙江我武生物科技股份有限公司于2026年9月30日召开第六届董事会第五次会议，审议通过选举YANNI CHEN（陈燕霓）女士为公司第六届董事会董事长，并选举其为代表公司执行公司事务的董事，担任公司法定代表人；同时聘任HU MUSHUANG（胡沐霜）女士为公司总经理，免去其副总经理职务。上述事项自董事会审议通过之日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793346045140,"stockEarnings":[{"period":"1week","weight":0.1235},{"period":"1month","weight":0.0696},{"period":"3month","weight":-0.104},{"period":"6month","weight":-0.1599},{"period":"1year","weight":-0.3816},{"period":"ytd","weight":-0.2449}],"compareEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":-0.0467},{"period":"3month","weight":-0.0472},{"period":"6month","weight":-0.112},{"period":"1year","weight":-0.0909},{"period":"ytd","weight":-0.08}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39172人(较上一季度增加11.09%)","perCapita":"12112股","listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","registeredCapital":"52358万元","survey":" 浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。","listedPrice":20.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}